Q1 2025 13F Holders as of 31 Mar 2025
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
98,294,118
-
Total 13F shares
-
76,226,291
-
Share change
-
+4,927,610
-
Total reported value
-
$958,937,759
-
Put/Call ratio
-
215%
-
Price per share
-
$12.58
-
Number of holders
-
182
-
Value change
-
+$63,838,841
-
Number of buys
-
96
-
Number of sells
-
74
Institutional Holders of ARS Pharmaceuticals, Inc. - Common Stock (SPRY) as of Q1 2025
As of 31 Mar 2025,
ARS Pharmaceuticals, Inc. - Common Stock (SPRY) was held by
182 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
76,226,291 shares.
The largest 10 holders included
RA CAPITAL MANAGEMENT, L.P., DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C), ORBIMED ADVISORS LLC, BlackRock, Inc., SR One Capital Management, LP, ALLIANCEBERNSTEIN L.P., VANGUARD GROUP INC, STATE STREET CORP, FRANKLIN RESOURCES INC, and Cormorant Asset Management, LP.
This page lists
182
institutional shareholders reporting positions in this security
for the Q1 2025 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.